Abstract:ERAP1 is an enzyme that plays a key role in the antigen processing and presentation pathway as an editor of the peptide repertoire, allowing for the binding of neoantigens to MHC I. ERAP1 is polymorphic, with the different allelic variants showing various degrees of peptide trimming function expressed in humans. However, the trimming mechanism by which ERAP1 trims peptides is still not fully understood. The purpose of the study is to characterize the effect of the different ERAP1 variants and their inhibition on the peptide repertoire presented by tumor cells, enabling us to gain valuable insights into how this process works. This characterization will also enhance the pharmacological modulation of ERAP1, which has already been proven to promote T cell and NK-mediated anti-tumor cytotoxic response. By specifically targeting the activity levels of the ERAP1 variant expressed, we can adopt a personalized approach that maximizes the potential production of neoantigens, crucial for activating an anti-tumor immune response. We CRISPR knocked out the ERAP1 gene in the CT26 cell line and assessed the MHC I kinetics and stability by investigating the dissociation of pMHC complexes at the cell surface, using a Brefeldin-A decay assay and an acid-stripping test compared to wild-type. The assessment of MHC I assembly and cell surface expression kinetics showed higher MHC I in the ERAP1 KO cell line, highlighting that the lack of ERAP1 translated into a faster recovery time of peptide/MHC complexes at the cell surface. After assessing the kinetics, we re-expressed different human ERAP1 allotypes in CT26 ERAP1KO cell line through retroviral transduction and characterized MHC I expression levels through flow cytometry. Interestingly, MHC I expression levels varied across the transduced samples, with specific variants showing much higher expression levels indicating more peptide availability for loading onto the MHC molecules. Immunopeptidomic analysis comparing the WT, ERAP1 KO and the CT26 human ERAP1 transduced cell lines, showed distinct subsets of neoantigens presented in the KO cell line. ERAP1 plays a significant role in the assembly and recovery of peptide/MHC complexes. The reintroduction of different ERAP1 allelic variants greatly alters MHC I expression levels suggesting the formation of new peptide-MHC complexes responsible for the increase in MHC I expression. Modulation of ERAP1 activity significantly alters the presented peptide repertoire , uncovering neoantigens which are potentially immunogenic. Citation Format: Shami Alvarez Mourid, Edward James, Dario Guglietta, Emma Reeves. Effects of modulation of ERAP1 activity in antigen processing and presentation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB367.

ERAP Inhibitors in Autoimmunity and Immuno-Oncology: Medicinal Chemistry Insights

ERAP1: a potential therapeutic target for a myriad of diseases

Crystal Structures of ERAP2 Complexed with Inhibitors Reveal Pharmacophore Requirements for Optimizing Inhibitor Potency.

ERAP1 activity modulates the immunopeptidome but also affects the proteome, metabolism and stress responses in cancer cells

Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint

Carnosic Acid: A Novel Selective Inhibitor of ERAP1 by Direct Binding and Its Modulation of Antigen Processing and Presentation

Abstract LB367: Effects of modulation of ERAP1 activity in antigen processing and presentation

A high-throughput MALDI-TOF MS biochemical screen for small molecule inhibitors of the antigen aminopeptidase ERAP1

The Role of Aminopeptidase ERAP1 in Human Pathology—A Review

Structural Basis for Antigenic Peptide Recognition and Processing by Endoplasmic Reticulum (ER) Aminopeptidase 2

Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB

Stabilization of the open conformation οf Insulin-Regulated Aminopeptidase by a novel substrate-selective small molecule inhibitor

To Be or Not to Be: The Case of Endoplasmic Reticulum Aminopeptidase 2

Stabilization of the open conformation οf insulin‐regulated aminopeptidase by a novel substrate‐selective small‐molecule inhibitor

Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases

Epitope landscape in autoimmune neurological disease and beyond

The abscopal effect: Implications for drug discovery in autoimmunity

Immune Checkpoints as Therapeutic Targets in Autoimmunity

Unveiling the Proteome-Wide Autoreactome Enables Enhanced Evaluation of Emerging CAR T Cell Therapies in Autoimmunity

Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies